Alterity Therapeutics Limited

ASX:ATH Stock Report

Market Cap: AU$31.4m

Alterity Therapeutics Management

Management criteria checks 2/4

Alterity Therapeutics' CEO is David Stamler, appointed in Jan 2021, has a tenure of 3.25 years. total yearly compensation is A$1.65M, comprised of 44.3% salary and 55.7% bonuses, including company stock and options. directly owns 0.068% of the company’s shares, worth A$21.33K. The average tenure of the management team and the board of directors is 12.3 years and 17.9 years respectively.

Key information

David Stamler

Chief executive officer

AU$1.6m

Total compensation

CEO salary percentage44.3%
CEO tenure3.3yrs
CEO ownership0.07%
Management average tenure12.3yrs
Board average tenure17.9yrs

Recent management updates

Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

Nov 23
Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

Recent updates

Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

Nov 23
Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

We're Keeping An Eye On Alterity Therapeutics' (ASX:ATH) Cash Burn Rate

Jun 28
We're Keeping An Eye On Alterity Therapeutics' (ASX:ATH) Cash Burn Rate

Is Alterity Therapeutics (ASX:ATH) In A Good Position To Invest In Growth?

Mar 07
Is Alterity Therapeutics (ASX:ATH) In A Good Position To Invest In Growth?

We're Hopeful That Alterity Therapeutics (ASX:ATH) Will Use Its Cash Wisely

May 16
We're Hopeful That Alterity Therapeutics (ASX:ATH) Will Use Its Cash Wisely

Here's Why We're Watching Alterity Therapeutics' (ASX:ATH) Cash Burn Situation

Jan 31
Here's Why We're Watching Alterity Therapeutics' (ASX:ATH) Cash Burn Situation

How Much Is Alterity Therapeutics Limited (ASX:ATH) CEO Getting Paid?

Dec 09
How Much Is Alterity Therapeutics Limited (ASX:ATH) CEO Getting Paid?

CEO Compensation Analysis

How has David Stamler's remuneration changed compared to Alterity Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-AU$12m

Sep 30 2023n/an/a

-AU$13m

Jun 30 2023AU$2mAU$731k

-AU$14m

Mar 31 2023n/an/a

-AU$14m

Dec 31 2022n/an/a

-AU$14m

Sep 30 2022n/an/a

-AU$14m

Jun 30 2022AU$2mAU$658k

-AU$13m

Mar 31 2022n/an/a

-AU$13m

Dec 31 2021n/an/a

-AU$13m

Sep 30 2021n/an/a

-AU$14m

Jun 30 2021AU$979kAU$606k

-AU$15m

Mar 31 2021n/an/a

-AU$16m

Dec 31 2020n/an/a

-AU$16m

Sep 30 2020n/an/a

-AU$15m

Jun 30 2020AU$625kAU$625k

-AU$13m

Mar 31 2020n/an/a

-AU$13m

Dec 31 2019n/an/a

-AU$13m

Sep 30 2019n/an/a

-AU$12m

Jun 30 2019AU$548kAU$548k

-AU$12m

Mar 31 2019n/an/a

-AU$11m

Dec 31 2018n/an/a

-AU$10m

Sep 30 2018n/an/a

-AU$9m

Jun 30 2018AU$630kAU$504k

-AU$8m

Mar 31 2018n/an/a

-AU$8m

Dec 31 2017n/an/a

-AU$8m

Sep 30 2017n/an/a

-AU$8m

Jun 30 2017AU$588kAU$519k

-AU$8m

Compensation vs Market: David's total compensation ($USD1.08M) is above average for companies of similar size in the Australian market ($USD290.69K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Stamler (62 yo)

3.3yrs

Tenure

AU$1,649,998

Compensation

Dr. David A. Stamler, M.D., serves as Chief Executive Officer at Alterity Therapeutics Limited since January 07, 2021. Dr. Stamler had been the Chief Medical Officer and Senior Vice President of Clinical D...

Leadership Team

NamePositionTenureCompensationOwnership
Geoffrey Kempler
Co-Founder & Non-Executive Chairman26.4yrsAU$313.30k0.34%
A$ 108.1k
David Stamler
Chief Executive Officer3.3yrsAU$1.65m0.068%
A$ 21.3k
Phillip Hains
CFO & Company Secretary9.4yrsno datano data
Rudolph Tanzi
Chief Scientific Advisor and Member of Research & Development Advisory Board12.3yrsno datano data
Steven Targum
Chief Medical Advisor17.1yrsno datano data
Robert Cherny
Head of Research17yrsno datano data

12.3yrs

Average Tenure

64yo

Average Age

Experienced Management: ATH's management team is seasoned and experienced (12.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Geoffrey Kempler
Co-Founder & Non-Executive Chairman26.4yrsAU$313.30k0.34%
A$ 108.1k
Rudolph Tanzi
Chief Scientific Advisor and Member of Research & Development Advisory Board17.1yrsno datano data
Brian Meltzer
Non-Executive Independent Director24.3yrsAU$70.00k0.14%
A$ 44.8k
Colin Masters
Member of Research & Development Advisory Board17.1yrsAU$241.36kno data
Peter Marks
Non-Executive Independent Director18.8yrsAU$70.00k0.14%
A$ 43.1k
Lawrence Gozlan
Non-Executive Director12.7yrsAU$70.00kno data
Ira Shoulson
Chairman of Research & Development Advisory Boardno dataAU$78.76kno data

17.9yrs

Average Tenure

68yo

Average Age

Experienced Board: ATH's board of directors are seasoned and experienced ( 17.9 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.